Alpha Omega Wealth Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.1M | Sell |
47,949
-1,140
| -2% | -$245K | 1.84% | 9 |
|
|
2026
Q1 | $10.7M | Buy |
49,089
+216
| +0.4% | +$47.9K | 1.73% | 11 |
|
|
2025
Q4 | $11.2M | Sell |
48,873
-349
| -0.7% | -$79.5K | 1.85% | 10 |
|
|
2025
Q3 | $11.4M | Sell |
49,222
-255
| -0.5% | -$51.9K | 1.9% | 7 |
|
|
2025
Q2 | $9.18M | Sell |
49,477
-218
| -0.4% | -$40.5K | 1.64% | 14 |
|
|
2025
Q1 | $10.4M | Sell |
49,695
-4,965
| -9% | -$965K | 1.99% | 6 |
|
|
2024
Q4 | $9.71M | Sell |
54,660
-351
| -0.6% | -$64.5K | 1.84% | 8 |
|
|
2024
Q3 | $10.9M | Sell |
55,011
-1,509
| -3% | -$282K | 1.99% | 6 |
|
|
2024
Q2 | $9.69M | Sell |
56,520
-1,346
| -2% | -$223K | 1.85% | 7 |
|
|
2024
Q1 | $10.5M | Sell |
57,866
-2,011
| -3% | -$347K | 1.96% | 7 |
|
|
2023
Q4 | $9.28M | Sell |
59,877
-1,176
| -2% | -$171K | 1.54% | 7 |
|
|
2023
Q3 | $9.1M | Sell |
61,053
-608
| -1% | -$89.3K | 1.57% | 9 |
|
|
2023
Q2 | $8.31M | Sell |
61,661
-1,483
| -2% | -$217K | 1.4% | 11 |
|
|
2023
Q1 | $10.1M | Sell |
63,144
-375
| -0.6% | -$57.3K | 1.74% | 6 |
|
|
2022
Q4 | $10.3M | Sell |
63,519
-1,161
| -2% | -$178K | 1.82% | 6 |
|
|
2022
Q3 | $8.68M | Sell |
64,680
-590
| -0.9% | -$84.7K | 1.66% | 9 |
|
|
2022
Q2 | $10M | Sell |
65,270
-1,216
| -2% | -$186K | 1.79% | 7 |
|
|
2022
Q1 | $10.8M | Sell |
66,486
-18,177
| -21% | -$2.64M | 1.7% | 6 |
|
|
2021
Q4 | $11.3M | Sell |
84,663
-36
| -0% | -$4.25K | 1.74% | 7 |
|
|
2021
Q3 | $9.14M | Sell |
84,699
-427
| -0.5% | -$48.8K | 1.49% | 9 |
|
|
2021
Q2 | $9.59M | Buy |
85,126
+82
| +0.1% | +$9.23K | 1.57% | 9 |
|
|
2021
Q1 | $9.2M | Buy |
85,044
+19,321
| +29% | +$2.07M | 1.61% | 9 |
|
|
2020
Q4 | $7.04M | Buy |
65,723
+335
| +0.5% | +$32.2K | 1.19% | 9 |
|
|
2020
Q3 | $5.73M | Buy |
65,388
+20,388
| +45% | +$1.92M | 0.81% | 10 |
|
|
2020
Q2 | $4.42M | Buy |
45,000
+33,966
| +308% | +$2.99M | 0.67% | 16 |
|
|
2020
Q1 | $841K | Sell |
11,034
-531
| -5% | -$45.2K | 0.16% | 94 |
|
|
2019
Q4 | $1.02M | Buy |
11,565
+42
| +0.4% | +$3.49K | 0.16% | 99 |
|
|
2019
Q3 | $982K | Buy |
11,523
+1,859
| +19% | +$127K | 0.16% | 101 |
|
|
2019
Q2 | $703K | Sell |
9,664
-113
| -1% | -$8.88K | 0.3% | 71 |
|
|
2019
Q1 | $788K | Sell |
9,777
-275
| -3% | -$22.5K | 0.35% | 65 |
|
|
2018
Q4 | $927K | Hold |
10,052
| – | – | 0.47% | 56 |
|
|
2018
Q3 | $951K | Sell |
10,052
-25
| -0.2% | -$2.37K | 0.43% | 56 |
|
|
2018
Q2 | $934K | Sell |
10,077
-435
| -4% | -$42.5K | 0.46% | 56 |
|
|
2018
Q1 | $995K | Sell |
10,512
-140
| -1% | -$15.4K | 0.5% | 54 |
|
|
2017
Q4 | $1.03M | Sell |
10,652
-734
| -6% | -$69.2K | 0.5% | 52 |
|
|
2017
Q3 | $1.01M | Sell |
11,386
-400
| -3% | -$30.4K | 0.5% | 53 |
|
|
2017
Q2 | $855K | Hold |
11,786
| – | – | 0.44% | 57 |
|
|
2017
Q1 | $768K | Hold |
11,786
| – | – | 0.41% | 61 |
|
|
2016
Q4 | $738K | Buy |
11,786
+11,211
| +1,950% | +$684K | 0.39% | 62 |
|
|
2016
Q3 | $36K | Hold |
575
| – | – | 0.03% | 119 |
|
|
2016
Q2 | $36K | Hold |
575
| – | – | 0.03% | 119 |
|
|
2016
Q1 | $33K | Buy |
575
+475
| +475% | +$26.5K | 0.03% | 118 |
|
|
2015
Q4 | $6K | Buy |
+100
| New | +$5.76K | 0.01% | 179 |
|
Other funds holding ABBV
ECSS
ATO
Alpha Omega Wealth Management's ABBV Position: Q2 2026 in Review
Alpha Omega Wealth Management reduced its AbbVie (ABBV) stake by 2.3% in Q2 2026, selling an estimated $245K and leaving 47,949 shares worth $12.1M. The position accounts for 1.84% of the portfolio, ranked #9.
Alpha Omega Wealth Management first reported a position in ABBV in Q4 2015 and has held it in 43 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Alpha Omega Wealth Management held 47,949 shares of AbbVie worth $12.1M as of Q2 2026.
- Alpha Omega Wealth Management sold 1,140 AbbVie shares in Q2 2026, an estimated $245K.
- AbbVie made up 1.84% of Alpha Omega Wealth Management's portfolio in Q2 2026, its #9 holding.
- Alpha Omega Wealth Management first reported a position in AbbVie in Q4 2015 and has held it in 43 quarters since.
- 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Alpha Omega Wealth Management's 13F filing for Q2 2026, filed 20 Jul 2026.